Cargando…
The Chemokine CXCL16 Is a New Biomarker for Lymph Node Analysis of Colon Cancer Outcome
Chemokines are important in the development and progression of tumors. We investigated the expression of CXCL14 and CXCL16 in colon cancer. Expression of mRNA was assessed in primary tumors and lymph nodes and CXCL16 mRNA levels were correlated to patient’s survival. Protein expression was investiga...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888697/ https://www.ncbi.nlm.nih.gov/pubmed/31752131 http://dx.doi.org/10.3390/ijms20225793 |
_version_ | 1783475290274529280 |
---|---|
author | AbdelMageed, Manar Ali, Haytham Olsson, Lina Lindmark, Gudrun Hammarström, Marie-Louise Hammarström, Sten Sitohy, Basel |
author_facet | AbdelMageed, Manar Ali, Haytham Olsson, Lina Lindmark, Gudrun Hammarström, Marie-Louise Hammarström, Sten Sitohy, Basel |
author_sort | AbdelMageed, Manar |
collection | PubMed |
description | Chemokines are important in the development and progression of tumors. We investigated the expression of CXCL14 and CXCL16 in colon cancer. Expression of mRNA was assessed in primary tumors and lymph nodes and CXCL16 mRNA levels were correlated to patient’s survival. Protein expression was investigated by two-color immunofluorescence and immunomorphometry. CXCL14 and CXCL16 mRNA levels and protein expression were significantly higher in colon cancer primary tumors compared to apparently normal colon tissue. Positive cells were tumor cells, as revealed by anti-CEA and anti-EpCAM staining. CXCL16, but not CXCL14, mRNA levels were significantly higher in hematoxylin and eosin positive (H&E(+)) compared to H&E(−) colon cancer lymph nodes or control nodes (P < 0.0001). CXCL16 mRNA was expressed in 5/5 colon cancer cell lines while CXCL14 was expressed significantly in only one. Kaplan-Meier analysis revealed that colon cancer patients with lymph nodes expressing high or very high levels (7.2 and 11.4 copies/18S rRNA unit, respectively) of CXCL16 mRNA had a decreased mean survival time of 30 and 46 months at the 12-year follow-up (P = 0.04, P = 0.005, respectively). In conclusion, high expression of CXCL16 mRNA in regional lymph nodes of colon cancer patients is a sign of a poor prognosis. |
format | Online Article Text |
id | pubmed-6888697 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68886972019-12-09 The Chemokine CXCL16 Is a New Biomarker for Lymph Node Analysis of Colon Cancer Outcome AbdelMageed, Manar Ali, Haytham Olsson, Lina Lindmark, Gudrun Hammarström, Marie-Louise Hammarström, Sten Sitohy, Basel Int J Mol Sci Article Chemokines are important in the development and progression of tumors. We investigated the expression of CXCL14 and CXCL16 in colon cancer. Expression of mRNA was assessed in primary tumors and lymph nodes and CXCL16 mRNA levels were correlated to patient’s survival. Protein expression was investigated by two-color immunofluorescence and immunomorphometry. CXCL14 and CXCL16 mRNA levels and protein expression were significantly higher in colon cancer primary tumors compared to apparently normal colon tissue. Positive cells were tumor cells, as revealed by anti-CEA and anti-EpCAM staining. CXCL16, but not CXCL14, mRNA levels were significantly higher in hematoxylin and eosin positive (H&E(+)) compared to H&E(−) colon cancer lymph nodes or control nodes (P < 0.0001). CXCL16 mRNA was expressed in 5/5 colon cancer cell lines while CXCL14 was expressed significantly in only one. Kaplan-Meier analysis revealed that colon cancer patients with lymph nodes expressing high or very high levels (7.2 and 11.4 copies/18S rRNA unit, respectively) of CXCL16 mRNA had a decreased mean survival time of 30 and 46 months at the 12-year follow-up (P = 0.04, P = 0.005, respectively). In conclusion, high expression of CXCL16 mRNA in regional lymph nodes of colon cancer patients is a sign of a poor prognosis. MDPI 2019-11-18 /pmc/articles/PMC6888697/ /pubmed/31752131 http://dx.doi.org/10.3390/ijms20225793 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article AbdelMageed, Manar Ali, Haytham Olsson, Lina Lindmark, Gudrun Hammarström, Marie-Louise Hammarström, Sten Sitohy, Basel The Chemokine CXCL16 Is a New Biomarker for Lymph Node Analysis of Colon Cancer Outcome |
title | The Chemokine CXCL16 Is a New Biomarker for Lymph Node Analysis of Colon Cancer Outcome |
title_full | The Chemokine CXCL16 Is a New Biomarker for Lymph Node Analysis of Colon Cancer Outcome |
title_fullStr | The Chemokine CXCL16 Is a New Biomarker for Lymph Node Analysis of Colon Cancer Outcome |
title_full_unstemmed | The Chemokine CXCL16 Is a New Biomarker for Lymph Node Analysis of Colon Cancer Outcome |
title_short | The Chemokine CXCL16 Is a New Biomarker for Lymph Node Analysis of Colon Cancer Outcome |
title_sort | chemokine cxcl16 is a new biomarker for lymph node analysis of colon cancer outcome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6888697/ https://www.ncbi.nlm.nih.gov/pubmed/31752131 http://dx.doi.org/10.3390/ijms20225793 |
work_keys_str_mv | AT abdelmageedmanar thechemokinecxcl16isanewbiomarkerforlymphnodeanalysisofcoloncanceroutcome AT alihaytham thechemokinecxcl16isanewbiomarkerforlymphnodeanalysisofcoloncanceroutcome AT olssonlina thechemokinecxcl16isanewbiomarkerforlymphnodeanalysisofcoloncanceroutcome AT lindmarkgudrun thechemokinecxcl16isanewbiomarkerforlymphnodeanalysisofcoloncanceroutcome AT hammarstrommarielouise thechemokinecxcl16isanewbiomarkerforlymphnodeanalysisofcoloncanceroutcome AT hammarstromsten thechemokinecxcl16isanewbiomarkerforlymphnodeanalysisofcoloncanceroutcome AT sitohybasel thechemokinecxcl16isanewbiomarkerforlymphnodeanalysisofcoloncanceroutcome AT abdelmageedmanar chemokinecxcl16isanewbiomarkerforlymphnodeanalysisofcoloncanceroutcome AT alihaytham chemokinecxcl16isanewbiomarkerforlymphnodeanalysisofcoloncanceroutcome AT olssonlina chemokinecxcl16isanewbiomarkerforlymphnodeanalysisofcoloncanceroutcome AT lindmarkgudrun chemokinecxcl16isanewbiomarkerforlymphnodeanalysisofcoloncanceroutcome AT hammarstrommarielouise chemokinecxcl16isanewbiomarkerforlymphnodeanalysisofcoloncanceroutcome AT hammarstromsten chemokinecxcl16isanewbiomarkerforlymphnodeanalysisofcoloncanceroutcome AT sitohybasel chemokinecxcl16isanewbiomarkerforlymphnodeanalysisofcoloncanceroutcome |